NCT04041193 (SIDERA^B) is a NA clinical trial of SIDERA^B in Parkinson Disease (PD), sponsored by Fondazione Don Carlo Gnocchi Onlus.

Who is sponsoring NCT04041193?

NCT04041193 is sponsored by Fondazione Don Carlo Gnocchi Onlus.

What drugs are being tested in NCT04041193?

Interventions in NCT04041193: SIDERA^B, Usual Care Program.

What condition does NCT04041193 study?

NCT04041193 studies Parkinson Disease (PD), Chronic Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD).

Is NCT04041193 still recruiting?

NCT04041193 is currently status unknown. Last updated 17 June 2020.

Last reviewed 2020-06-17 · How we verify

NCT04041193: SIDERA^B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Innovative Disease-net Management Model for Non-communicable Diseases (SIDERA^B)

Status unknown NA Last updated 17 June 2020

What this trial tests

NA trial testing SIDERA^B in Parkinson Disease (PD) in 150 participants. Status unknown.

Timeline

29 July 2019

Primary endpoint
15 October 2020

1 January 2021

Quick facts

Lead sponsor	Fondazione Don Carlo Gnocchi Onlus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	150
Start date	29 July 2019
Primary completion	15 October 2020
Estimated completion	1 January 2021
Sites	1 location across Italy

Drugs / interventions tested

SIDERA^B
Usual Care Program

Conditions studied

Parkinson Disease (PD) — all drugs for Parkinson Disease (PD) →
Chronic Heart Failure (CHF) — all drugs for Chronic Heart Failure (CHF) →
Chronic Obstructive Pulmonary Disease (COPD) — all drugs for Chronic Obstructive Pulmonary Disease (COPD) →

Sponsor

Fondazione Don Carlo Gnocchi Onlus — full company profile →

Who can join

Adults 18 to 85, any sex, with Parkinson Disease (PD) or Chronic Heart Failure (CHF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SIDERA\^B telerehabilitation system is enabled by a multi-domain, multi-device platform providing at home multi-component rehabilitation, targeting cardiovascular (Chronic Heart Failure, CHF), pulmonary (Chronic Obstructive Pulmonary Disease, COPD) and neurodegenerative (Parkinson Disease, PD) chronic diseases. The rehabilitation program embeds engagement activities for patient and caregiver, to empower appropriation of the SIDERA\^B care routines and fuel their well-being resources. The multidisciplinary layering of SIDERA\^B is reflected in the validation protocol including a) clinical and well-being evaluation through a cross-over study confronting usual care with the SIDERA\^B activities; b) technological evaluation: Health Technology Assessment for organizational, legal and equity impacts; c) economic evaluation: process mapping and budget impact analysis to define a sustainable reimbursement process for the innovative telerehabilitation pathway.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

System Integrated Digital Empowerment and Rehabilitation to promote patient Activation and well-Being (SIDERA^B): Protocol for a Randomized Crossover Trial on Effectiveness and Implementation
Rossetto F, Borgnis F, Blasi V, Banfi PI, et al · · 2022 · DOI 10.1101/2022.04.19.22274012

Verify or expand the search:

Other recruiting trials for Parkinson Disease (PD)

Currently open trials in the same condition.

NCT07176286 — 18F-mFBG Cardiac Uptake With Lewy Body Dementia · Phase 2 · recruiting
NCT07495462 — Effect of Motor Imagery Added to Rehabilitation on Balance and Kinesiophobia in Patients With Parkinson's Disease · NA · recruiting
NCT07308795 — The Ultrasonographic Evaluation of Abdominal Accessory Respiratory Muscle Thickness in Patients With Parkinson's Disease · recruiting
NCT07302386 — Exercise Management in Parkinson's Disease · NA · recruiting
NCT07157345 — Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease · Phase 1 · recruiting

Other Fondazione Don Carlo Gnocchi Onlus trials

Trials by the same sponsor.

NCT07252856 — Transcultural Digital Solutions in Phase III Cardiac Rehabilitation · NA · not yet recruiting
NCT07290218 — Tridimensional Robotic Assessment of Neglect in Brain Injured Patients · not yet recruiting
NCT07064226 — Validation of a Digital Intervention to Rehabilitate Cognitive Resources · NA · recruiting
NCT07130929 — Functional Electrical Stimulation to Treat Critical Neuromyopathy After Severe Stroke: a Pilot Study. · NA · recruiting
NCT07159854 — Telerehabilitation in Central and Peripheral Neurological Sequelae From Chemotherapy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04041193 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Don Carlo Gnocchi Onlus
Last refreshed: 17 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04041193.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing